logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: News & Comments

Inovio: Good News About the Firm's COVID-19 Vaccine's Capability and Durability

Inovio Inovio’s COVID-19 Vaccine INO-4800 Accomplished the Following: Durable antibody and T cell responses in rhesus macaques for 4 months. Long-term protection in non-human primates challenged with SARS-CoV-2 virus 13     weeks from vaccination. No other vaccine has demonstrated...

Read More

July 30, 2020

0

Cassava Sciences Announces Positive Data with SavaDx from a Randomized Controlled Phase 2b Study of Simufilam

Cassava Sciences: Positive Clinical Data with SavaDX Cassava Sciences ( SAVA ) today announced positive clinical data with SavaDx, an investigational diagnostic/biomarker to detect Alzheimer’s disease with a simple blood test. SavaDx was used to measure plasma levels of altered filamin...

Read More

July 26, 2021

0

Cassava Sciences Inc: Today's Press Releases

Cassava Sciences Inc Press Release Related to Positive Biomarker Data  Cassava Sciences Inc ( SAVA ) announced today, in a press release , positive biomarker data from an open-label study of simufilam, the Company’s investigational drug for the treatment of...

Read More

July 29, 2021

0

Takeda Pharmaceutical Product LIVTENCITY Granted Approval by the FDA

Takeda Pharmaceutical Granted FDA Approval for LIVTENCITY for Post-Transplant Cytomegalovirus On November 23, 2021 Takeda Pharmaceutical Co Ltd ( TAK ) announced that the U.S. FDA has approved LIVTENCITY™ (maribavir) for adults and pediatric patients (12 years of age or...

Read More

November 25, 2021

0

Kazia Therapeutics Product Paxalisib Beats Temozolomide in Overall Survival in Mid-Phase Trial

The US FDA Awards Fast Track Designation to Paxalisib for Glioblastoma  Kazia Therapeutics Ltd ( KZIA ) - an Australian oncology biotechnology company, announced that the United States FDA has granted Fast Track Designation ( FTD ) to Kazia’s paxalisib for glioblastoma,...

Read More

August 25, 2020

0

BeiGene Ltd and EUSA Pharma Product QARZIBA® Approval from China NMPA. See Also: Sagimet Sciences and NASH  

BeiGene Ltd and EUSA Pharma Receive Approval from China NMPA for QARZIBA ®   BeiGene Ltd ( BGNE ) and  EUSA Pharma announced that China National Medical Products Administration ( NMPA ) has granted QARZIBA® (dinutuximab beta) conditional approval for...

Read More

August 17, 2021

0

The U.S. CDC Tells the 50 States to Prepare for COVID-19 Vaccines by the End of October

CDC Is Asking States to Prepare for COVID-19 Vaccines The U.S. Center of Disease Control and Prevention ( CDC ) has asked the 50 states' public health officials to be ready to distribute potential COVID-19 vaccines to high-risk people, healthcare...

Read More

September 3, 2020

0

Sanofi and GlaxoSmithKLine COVID-19 Vaccines are Advancing in Clinical Trial

Sanofi and GlaxoSmithKline Have COVID-19 Vaccines Advancing in Clinical Trial Sanofi ( SNY ) and GlaxoSmithKline ( GSK ) started Phase 1/2 clinical trial for their adjuvanted COVID-19 vaccine. The vaccine candidate developed by both firms uses the same recombinant...

Read More

September 3, 2020

0

The US FDA Granted Fast Track Designation for Sutro Biopharma Product STRO-002

Sutro Biopharma Inc Granted Fast Track Designation for STRO-002 by the US FDA Sutro Biopharma Inc ( STRO ) announced that the U.S. FDA granted Fast Track designation for its STRO-002 - a folate receptor alpha (FolRα)-targeting antibody-drug conjugate (ADC),...

Read More

August 18, 2021

0

The FDA Cleared the IND for Erasca Inc Product ERAS-801 for Recurrent Glioblastoma

Erasca Inc Product ERAS-801 IND Cleared by FDA Erasca Inc ( ERAS )  announced that the United States Food and Drug Administration ( FDA ) has cleared an investigational new drug ( IND ) application for ERAS-801, an orally available small...

Read More

December 17, 2021

0

  • Previous
  • 1
  • 2
  • ...
  • 97
  • 98
  • 99
  • ...
  • 115
  • 116
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy